ClinicalTrials.gg
AvailableNCT07783009Updated Nov 6, 2026

An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

An expanded access record providing Divarasib in Non-Small Cell Lung Cancer, sponsored by Genentech, Inc.. Available at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Expanded access

Updated Nov 6, 2026Now AvailableFirst site in United States+2 moreGo to Updates ↓
Study type
Expanded access
Access type
Treatment IND/protocol
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this expanded access program (EAP) is to provide early access to divarasib to participants with KRAS G12C-positive (KRAS G12C+) advanced or metastatic non-small cell lung cancer (NSCLC), prior to divarasib becoming commercially available in the United States.

02

Conditions studied

  • Non-Small Cell Lung Cancer
03

In context

Carcinoma, Non-Small-Cell Lung

7,620 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or NSCLC not amenable to treatment with surgical resection or combined chemoradiation
  • Disease progression during or after treatment with at least one prior standard of care systemic therapy but no more than three lines of prior systemic therapy in the advanced or metastatic setting, with the exceptions for /neoadjuvant therapies
  • Documentation of the presence of a KRAS G12C mutation obtained at any timepoint during the course of the disease
  • (ECOG) Performance Status of 0-2
  • of greater than or equal to 12 weeks
  • Ability to swallow tablets intact, without chewing or crushing

Exclusion criteria

Exclusion Criteria:

  • Previous enrollment in Roche- or Genentech-sponsored study of divarasib
  • Prior treatment with a pan-KRAS/RAS inhibitor
  • Prior treatment with a KRAS G12C inhibitor, unless specific criteria are met
  • Pregnant or breastfeeding, or intending to become pregnant during the EAP or within the timeframe in which is required
  • Known to any of the components of divarasib
  • Malabsorption syndrome or other condition that would interfere with enteral absorption
  • Mixed small-cell lung cancer
  • Known and untreated, or active (progressing or requiring anticonvulsants or for symptomatic control)
  • or carcinomatous meningitis
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures biweekly or more frequently
  • history of liver disease, including viral or other hepatitis, or cirrhosis
  • Known clinically significant history of liver disease consistent with Class B or C, including active viral or other hepatitis (ex: [HBV] or [HCV]) virus, current alcohol abuse or cirrhosis
  • Known positive infection
  • Significant traumatic injury or major surgical procedure within 4 weeks prior to initiation of EAP treatment
  • Chronic diarrhea, short bowel syndrome, or significant upper gastrointestinal surgery including gastric resection, a history of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or any active bowel inflammation (including diverticulitis)
  • Treatment with anti-cancer therapy (e.g., chemotherapy, immunotherapy, biologic therapy, or an anti-cancer agent) within 28 days prior to initiation of EAP treatment
  • More than 30 Gy of radiotherapy to the lung within 6 months prior to initiation of EAP treatment
  • Uncontrolled tumor-related pain where palliative care or hospice admission is planned, or where active pain management interventions are insufficient to alleviate symptoms
  • Unresolved toxicities from prior anti-cancer therapy, defined as not having resolved to v6.0 Grade 1 or better, or to levels dictated in the eligibility criteria or toxicities from prior anti-cancer therapy or palliative radiation therapy that are considered irreversible
  • Treatment with strong inhibitors or inducers within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to initiation of EAP treatment
  • Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the EAP
  • Blood or transfusion within 14 days prior to initiation of EAP treatment
  • History or presence of an abnormal that is deemed clinically significant (e.g., complete left bundle branch block, second- or third-degree atrioventricular heart block) or evidence of prior myocardial infarction
  • History of active that is currently receiving treatment or not well controlled
  • Significant cardiovascular disease, within 6 months of initiation of EAP treatment
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing), clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long syndrome
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

  • Participants will self-administer divarasib as per the schedule in the protocol.

    Also known as: RO7435846

06

Where to request access

2 of 2 sites recruiting
  • Billings Clinic Commons
    Billings, Montana 59101, United States
    Available
  • Baptist Clinical Research Institute
    Memphis, Tennessee 38120-2179, United States
    Available
07

References and documents

08

Updates

2 registry updates since Sep 25, 2026
Status
Temporarily not available→Available
changed Oct 9, 2026
Sites
3 sites added, 1 site removed — first site in United States
Show 3 added (3 United States)
  • Billings Clinic · Billings, United States
  • Billings Clinic Commons · Billings, United States
  • Baptist Clinical Research Institute · Memphis, United States
Show 1 removed
  • Billings Clinic · Billings, United States
across 2 updates, Oct 9, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    2 sites added, 1 site removed
    Show 2 added (2 United States)
    • Billings Clinic Commons · Billings, United States
    • Baptist Clinical Research Institute · Memphis, United States
    Show 1 removed
    • Billings Clinic · Billings, United States
    + 1 other change: verification date
  2. Oct 9, 2026
    Temporarily not available→Available
    1 site added — first site in United States
    Show site
    • Billings Clinic · Billings, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07783009
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Aug 24, 2026
Last update
Nov 6, 2026

Study contacts

Reference Study ID Number: AL46650 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 ext. (U.S. Only)
Fastest response: use the inquiry form. www.gene.com/contact-us/submit-medical-inquiry
Contact
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion